关于SUNGO公司 SUNGO是化的器械、食品企业法规技术服务商。 SUNGO包括三家公司,分别是位于美国的SUNGO Technical Service Inc.,位于英国的SUNGO Certification Company Limited和上海沙格企业管理咨询有限公司。 SUNGO的业务起源于2006年,在器械行业开展法规技术服务达10年之久,截止到目前累积客户超过1500家。其中包括很多业内的企业和上市企业,例如威高集团、恒安集团、暴龙眼镜、刚松股份、江苏鱼跃、河南羚锐等。 SUNGO始终追求支持、服务和客户满意。所有客户都有一对一的客服对接以保持经常性的联系,提供在线即时服务,针对贸易中存在的技术壁垒方面的问题提供的支持和解答。
![FDA认证](http://static.11467.com/img/lazy.gif)
审厂的触发原因包括: 一,例行检查; 二、FDA需要调查行业数据; 三,发生顾客抱怨,特别是多次的抱怨 四、发生较多的不良事件; 五,产品多次出现质量问题; 六、FDA接受其他管理局的委托进行审厂。比如,接受退伍军人管理局的委托。也可以主动申请审厂。有时候,你的美国客户,也可以申请FDA来审厂。审查不通过,只要后续措施得力,通常导致罚款之类的处罚。对审查的结果,应严格按照审核官的要求,提供详细的整改资料,立即停止销售。当然,有的整改措施是需要效果验证的。你就需要同时提交效果验证的证据。审厂不通过,直接导致罚款。
![FDA认证](http://static.11467.com/img/lazy.gif)
提供FDA注册,食品FDA注册、化妆品FDA注册,美国代理人服务、FDA验厂、FDA警告性移除
![FDA认证](http://static.11467.com/img/lazy.gif)
FDA对于美国代理人的解释也可以参考看一下网站的原文: Any foreign establishment engaged in the manufacture, preparation, propagation, compounding, or processing of a device imported into the United States must identify a United States agent (U.S. agent) for that establishment. Information about a foreign establishment’s U.S. Agent is submitted electronically using the FDA Unified Registration and Listing System (FURLS system) and is part of the establishment registration process. Each foreign establishment may designate only one U.S. agent. The foreign establishment may also, but is not required to, designate its U.S. agent as its official correspondent. The foreign establishment should provide the name, address, telephone and fax numbers, and e-mail address of the U.S. agent. The U.S. agent identified will be required to complete an automated process to confirm that they have agreed to act as the U.S. agent. The automated process will forward an email verification request to the U.S. agent. They will be re to confirm her/his consent to act as a representative/liaison on behalf of the foreign establishment. If the U.S. agent denies consent (or does not respond within 10 business days), the Official Correspondent/Owner Operator of the foreign establishment will be notified and must designate a new U.S. agent to satisfy the regulatory obligation.